Prescription medicine
Iothalamate Brand names: Cysto-Conray; first approved as Conray
Iothalamate (Cysto-Conray) is a prescription medicine with an FDA approval on record since 1962. No generic is listed in FDA's NDC Directory.
- No generic listed
- Boxed warning
Check it at the source: the iothalamate FDA label on DailyMed (effective December 31, 2020, Liebel-Flarsheim Company LLC); the NDA 13295 record on Drugs@FDA; every iothalamate label on DailyMed.
Highlights of the record
FDA label of December 31, 2020; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
NOT FOR INTRAVASCULAR ADMINISTRATION NOT FOR INTRATHECAL USE
Used for
From the label: indications and usageCysto-Conray II is indicated for use in retrograde cystography and cystourethrography.
Forms and strengths
- 172 mg/ml
Injection.
On the market
- Earliest approval on file
- August 16, 1962 Conray 43, Liebel-Flarsheim; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 16 through July 30, 2026
What is iothalamate used for?
From the label: indications and usageCysto-Conray II is indicated for use in retrograde cystography and cystourethrography.
FDA pharmacologic class: Radiographic Contrast Agent.
Source: FDA drug label (Cysto-Conray II), Liebel-Flarsheim Company LLC, effective December 31, 2020 (SPL set 8841ab4d-674d-4beb-88a5-13e35f6005cc), via openFDA; the full label on DailyMed
Is there a generic for iothalamate (Cysto-Conray)?
No generic iothalamate is approved (Drugs@FDA, October 8, 2026).
- 1962 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for iothalamate?
The FDA Adverse Event Reporting System holds 16 reports that list iothalamate among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 2 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other radiographic contrast agents
- the pharmacologic class, with prices and generics
- Iothalamate side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other